Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can induce anti-infliximab antibodies formation and result to loss of infliximab efficacy and active persistent disease. 2015; Vol.57, No.3 Received:May,2015 Accepted:June,2015 Introduction:
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Introduction:
Rheumatoid arthritis (RA) is a common systemic autoimmune disease can affect any tissues and organs but it mainly cause a chronic synovial inflammation of joints(1). Although the cause of RA still unknown, genetic and environmental factors play an important role in its pathogenic mechanisms(2). Because the inflammatory cytokines mainly interleukin-1(IL-1),interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) are elevated in synovial fluid and blood of patients with RA, so considered to be an association between these cytokines and pathogenesis of RA(3) Treatment of RA with biological agents mainly infliximab showed a great improvement in daily activities of patients with RA, this agent acts as TNF-α blocker (4) . Infliximab which is known as chimeric monoclonal antibody because it composed of constant region of human IgG1 and variable region of murine part target TNF-α,specifically binding with TNF-α result in the following outcome; neutralization of soluble TNF-α physiological effects; dissociation of TNF-α from complex with its receptor; and acts on cells produce TNF-α by the mechanisms include; antibody-dependent cell cytotoxicity(ADCC) , complement-dependent cytotoxicity (CDC) and apoptosis of these cells (5) (6) (7) . The infliximab is effective in the treatment of many autoimmune diseases such as RA (8), Ankylosing spondylitis (9), Psoriasis (10), Cronh`s disease(11) and Wegener`s garanulomatosis(12). Although,many patients with RA had a great initial effectiveness of infliximab treatment ,others not respond to this biological agents several months after treatment(13). In our study we investigated the development of anti-infliximab antibodies in patients with RA who had been received this biological treatment and then recorded the relationship between the effectiveness of this agent and emergence of these antibodies.
Patients and methods:
Fifty patients (36 females and 14 males), their mean age(45.3) years who attended to medical city, Baghdad teaching hospital,
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In table 4, the anti-infliximab anti-bodies were reported in patients age groups,10(66.7%)in patients with age (<=40) , 16 (76.2%)patients in between(41-50) years, and 9(64.3%) in patients age groups(>50%).On the other hand, these anti-bodies were negative in same age groups as follow (5(33.3%) in (<=40) ,5(23.8%) in (41-50) and 5(35.7) in (>50)respectively, show that no statistical difference between positive and negative anti-bodies in these patients age groups. Department of Rheumatology(Biological therapy unit) included in this study during period From begging of March 2014 till end of September 2014, all patients were treated with biological agent( intravenous infusion of Infliximab of 3 mg/ kg at baseline, and at 2 and 6 weeks then every 8 weeks), for least three months duration, all subset agreed to participated in research. The patients were compared to 50 control group ( 25 patients with RA on other treatment and 25 healthy individuals from central blood bank ) who were randomly selected as a control groups . All these patients met the revised criteria for RA (the American College of Rheumatology 1987) (14) and their disease activity was assessed by using Disease Activity Score in 28 joints(15,16) Samples of serum were collected from each patient with RA receive infliximab infusion for at least 3 months duration for assessment of anti-infliximab antibodies. Anti-infliximab antibodies were detected by enzyme-linked immunosorbent assay using Antibody to Infliximab ELISA kit (Matriks Biotek, Germany).
Results:
Fifty patients with RA (36 females and 14 males) their mean age was (45.24±9.15)years, and 50 control group(25 healthy and 25 case control),32 females and 18 males, their mean age was (42.22±8.23)years were included in this study as shown in table 1. 
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Discussion :
The rheumatoid arthritis is common autoimmune disease that more affected women than men in ratio 3:1 (17,18) ,the results of present study showed that nearly three quarter of the 50 Iraqi patients with RA who were treated with infliximab (3mg/kg) every 8 weeks developed antibodies to infliximab (IgG antibodies)within 3 months of treatment.Furthermore,development of these antibodies was related to decreased in response to infliximab treatment. Up to the best of our knowledge, this is the first study investigating of antibodies to infliximab in Iraqi patients with RA on infliximab infusion treatment who suffering from persistant active disease. In this study, we observed an increased in frequency of anti-infliximab anti-bodies in Iraqi patients with RA(P = 0.000001) which is highly significant and not detected in controls and majority of these anti-bodies were reported more in females patients than males since the disease in more common in female than male (3:1)(),this finding agreed with previous studies done by Gerrit and Marijin(19) .There are no relation of anti-infliximab anti-bodies development with patients age group (P = 0.711). Indeed ,patients with detectable anti-infliximab antibodies in their serum show lower respose to infliximab compared with patients without anti-infliximab anti-bodies .This indicates that formation of anti-bodies to infliximab induces the clearance of infliximab from circulation. Interestingly, we noted that in some patients who developed antiinfliximab antibodies that result in weak response to treatment, continuation of infliximab treatment with higher doses result in improvement in signs and symptoms of their diseases,This may be due to either infliximab cause induction of immune tolerance or overdosing the capacity of immune system to create these antibodies.
Conclusion :
Nearly three quarter of the Iraqi RA patients treated with infliximab developed anti-infliximab antibodies. 
